Trial Profile
A multicentre single arm study to evaluate the safety and efficacy of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (TE NDMM) patients refractory to initial bortezomib-based induction therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Thalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 10 Dec 2019 Results assessing preliminary data to confirm ulitilty of QIP MS and FLC MS for the sequential monitoring of tumour burden in Multiple myeloma patients, were presented at the 61st Annual Meeting and Exposition of the American Society of Hematology